Capecitabine/cisplatin versus 5 ‐fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re‐analysis of efficacy and safety data from the ML17032 phase III clinical trial

ConclusionXP had a similar safety profile and may demonstrate superiority for PFS compared to FP as first‐line treatment of Chinese patients with AGC (NCT02563054).

Source: Asia-Pacific Journal of Clinical Oncology - January 26, 2018 Category: Cancer & Oncology Authors: Jia Chen, Jianping Xiong, Jiejun Wang, Leizhen Zheng, YanFei Gao, Zhongzhen Guan Tags: ORIGINAL ARTICLE Source Type: research